Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/9228
Título: | Association between functional EGF+61polymorphism and glioma risk |
Autor(es): | Costa, Bruno Marques Ferreira, Paula Costa, Sandra Maria Araújo da Canedo, Paulo Oliveira, Pedro Silva, Ana Pardal, Fernando Suriano, Suriano Machado, José Carlos Lopes, José Manuel Reis, R. M. |
Data: | 1-Mai-2007 |
Editora: | American Association for Cancer Research (AACR) |
Revista: | Clinical Cancer Research |
Citação: | Costa, B. M., Ferreira, P., Costa, S., Canedo, P., Oliveira, P., Silva, A., … Reis, R. M. (2007, May 1). Association between Functional EGF+61 Polymorphism and Glioma Risk. Clinical Cancer Research. American Association for Cancer Research (AACR). http://doi.org/10.1158/1078-0432.ccr-06-2606 |
Resumo(s): | Epidermal growthf actor (EGF) plays a critical role in cancer. A polymorphism in the EGF gene (EGF+61) may influence its expression and contribute to cancer predisposition and aggressiveness. In the present study, we aimed to elucidate the role of EGF+61in glioma susceptibility and prognosis. Experimental Design:A case-control study involving197 glioma patients and 570 controlswas done. Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95% confidence intervals (95% CI). False-positive report probability was also assessed.The luciferase reporter gene assay was used to ascertain the functional consequences of this polymorphism. Results: Corroborating the univariate analysis, the multivariate model showed that the G allele conferred higher risks for gliomas (OR,1.32; 95% CI,1.04-1.67), glioblastomas (OR,1.47; 95% CI, 1.02-2.10), and oligodendrogliomas (OR,1.55; 95% CI,1.07-2.23).TheGG genotypeswere associatedwithincreased risk for gliomas (OR,1.71; 95%CI,1.07-2.73), glioblastomas (OR, 2.03; 95% CI, 1.02-4.05), and oligodendrogliomas (OR, 2.72; 95% CI, 1.18-6.28). In addition, the AG+GG genotypes were associated withhigher risk for gliomas (OR,1.52; 95% CI,1.03-2.23) and oligodendrogliomas (OR, 2.80; 95% CI,1.35-5.79). No significant associationwas observed between the EGF+61polymorphism and glioblastoma or oligodendroglioma patients’overall survival. The luciferase reporter gene assay exhibited a significant increased promoter activity for the G variant compared withthe referenceA allele. Conclusions: These findings support the role of the EGF+61polymorphism as a susceptibility factor for development of gliomas and show its implication on EGF promoter activity. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/9228 |
DOI: | 10.1158/1078-0432.CCR-06-2606 |
ISSN: | 1078-0432 |
Versão da editora: | http://clincancerres.aacrjournals.org/cgi/content/abstract/13/9/2621 |
Arbitragem científica: | yes |
Acesso: | Acesso aberto |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
EGF_ClinCanRes_2007.pdf | 141,88 kB | Adobe PDF | Ver/Abrir |